You are here:Home-Research Areas-Inflammation/Autoimmune Disease-Multiple Sclerosis

Request The Product List ofMultiple Sclerosis Multiple Sclerosis

Cat. No. Product Name CAS No. Information



An immunomodulatory agent can be phosphorylated by SphK, then functions as a potent agonist of S1P receptors (S1P1/3/4/5) with EC50 of 0.3-5 nM; has no affitnity for S1P2; alters lymphocyte trafficking and inhibits lymphocyte recirculation.

Multiple Sclerosis



Plerixafor octahydrochloride


Plerixafor octahydrochloride (JM-3100, AMD-3100, SID-791) is a potent, selective CXCR4 inhibitor (IC50=44 nM) that inhibits the replication of various HIV-1 and HIV-2 strains in various cell lines with EC50 of 10ng/ml; can produce mesenchymal stem cells and endothelial progenitor cells in mice in combination with VEGF; also is an allosteric agonist of CXCR7.

Multiple Sclerosis





Ozanimod (RPC-1063) is a potent, selective agonist of S1P1 and S1P5 receptor with EC50 of 0.41 nM and 11 nM respectively; less potent for S1P2, S1P3 and S1P4 (EC50> 10 uM); induces S1P1 receptor internalization and induced a reversible reduction in circulating B and CCR7(+) T lymphocytes in vivo; shows high oral bioavailability and volume of distribution, and a circulatory half-life.

Multiple Sclerosis

Phase 3 Clinical




Cenerimod (ACT-334441) is a potent and orally available S1P1 receptor agonist with EC50 of 2.7 nM; shows a powerful and long-lasting immunomodulating effect by reducing the number of circulating and infiltrating T- and B-lymphocytes, without affecting their maturation, memory, or expansion.

Multiple Sclerosis

Phase 1 Clinical


Guanabenz acetate

23256-50-0 Guanabenz acetate (Wytensin, WY-8678 acetate) is a small molecule that binds to PPP1R15A/GADD34, selectively disrupts the stress-induced dephosphorylation of eIF2α; prolongs eIF2α phosphorylation in human stressed cells, without affecting the related PPP1R15B-phosphatase complex and constitutive protein synthesis; accelerates ALS-like disease progression in a strain of mutant SOD1 transgenic ALS mice; exhibits anti-inflammatory activity by increasing in vitro IL-10 production by LPS-stimulated dendritic cells, prevents d-Galactosamine/LPS-induced liver damage and mortality in vivo.

Multiple Sclerosis

Phase 1 Discontinued



618913-30-7 AZD5904 (AZD-5904) is a potent, selective irreversible, orally bioavailable myeloperoxidase (MPO) inhibitor with IC50 of 140 nM, similar potency in mouse and rat; displays 10 to 19-fold selective compared to the closely related lactoperoxidase and thyroid peroxidase, >70-fold to a broad panel of other enzymes, ion channels, and receptors; 1 µM AZD5904 inhibited PMA stimulated HOCl by >90% in isolated human neutrophils; a plasma concentration of ~5 µM decreased the in vivo formation of glutathione sulphonamide in rats.

Multiple Sclerosis

Phase 1 Discontinued



248281-84-7 Laquinimod (ABR-215062) is an immunoregulator derived from Linomide, has been shown to completely inhibit the development of murine acute experimental autoimmune encephalomyelitis (EAE); dose-dependently reduces the incidence of EAN, ameliorated clinical signs and inhibited P0 peptide 180-199-specific T cell responses as well as also the decreased inflammation and demyelination in the peripheral nerves; shows improved potency and superior toxicological profile compared to the lead compound Roquinimex (Linomide).

Multiple Sclerosis


Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us